Healthcare
Sandoz launches high‑volume biosimilar drug substance plant in Slovenia
Sandoz opened a high‑tech, high‑volume biosimilar drug substance manufacturing centre in Lendava, Slovenia, employing over 300 experts and bolstering its Bio100 target of 100 biosimilars by 2040.
DocMorris shares rise 10% as target raised, Redcare lagging
DocMorris stock has doubled year‑to‑date after a 10% jump, with Research Partners lifting its price target to CHF 14.60. Analyst compares it with slower‑gaining rival Redcare Pharmacy.
Roche pushes aggressive pipeline expansion at Pharma Day, cites AI and new "Bar" criteria
Roche outlined a goal of up to 20 new drugs by 2030, introduced a stricter "Bar" framework for candidate selection and highlighted artificial‑intelligence integration across research, aiming for >30 bn CHF sales from top prospects.
Bernstein Names Sonova, Alcon Top European Medtech Picks for H2
The firm highlighted Sonova as its short-term top pick and Alcon as the preferred long-term play, citing strong fundamentals in hearing aids and ophthalmology.
EU Approves Roche’s Susvimo for Neovascular AMD Treatment
The European Commission has granted marketing authorization for Roche’s implant-based Susvimo, marking the first continuous-delivery option for neovascular age-related macular degeneration.
AEVIS Victoria H1 2026 profit gains lift shares 4.4% to $14.3
AEVIS Victoria reported a 6.9% rise in NAV to CHF 26.75 per share and a 43% drop in interest expense, sending its stock 4.38% higher to a new 52‑week high of $14.30.
Aevis Victoria lifts H1 2026 profit 30%, revenue edges up
The Swiss holding group posted a 30% rise in net profit to CHF 5.4 million, driven by stronger healthcare and hospitality margins.
US stocks set for mixed open as oil nears $100 and rate-hike odds rise
Dow seen 0.8% lower at 53,013 and Nasdaq 100 0.1% higher at 29,568, while Brent tops $98 and ECB and US rate-hike expectations weigh on sentiment.
Ligand Pharmaceuticals posts 34% revenue rise, raises 2024 EPS guidance
Royalty-focused biotech reports Q2 results and outlines growth strategy at Midwest IDEAS Conference. Shares up 76% over past year.
Molecular Partners extends cash runway to 2027, advances cancer drug pipeline
Swiss biotech firm raises next dose level for experimental DLL3-targeting therapy MP0712 while reducing R&D spend. Loss narrows to 26.7 million francs in H1 2026.
Sonova launches Phonak EON hearing aids with third-gen real-time AI
Swiss hearing tech leader Sonova unveils Phonak EON portfolio featuring proprietary AI chip, 37% energy savings and 50 dB wind-noise reduction. U.S. launch begins Aug. 24.
GSK’s bepirovirsen wins Japan approval as first global hepatitis B cure
Japan’s regulator grants accelerated approval for GSK’s antisense drug, targeting adults with chronic hepatitis B who have failed prior therapies. Global filings underway.
Swiss nursing home costs top 10,000 francs monthly on average
Average stay exceeds two years, with monthly expenses ranging from 4,500 to 8,000 francs for residents. Public subsidies cover the remainder, but rising costs outpace pensions.
Optima Health sets Sept. 22 AGM, releases 2026 annual report
Healthcare services provider Optima Health scheduled its annual general meeting for Sept. 22 and issued its 2026 annual report to shareholders. Shares closed at 238 pence on Aug. 20.
Moderna, Merck mRNA cancer vaccine hits milestone in melanoma trial
Combined therapy shows first late-stage success for personalized mRNA cancer vaccine, driving Moderna shares up 150%. Keytruda patent cliff looms as rivals race to replicate results.
Genentech to invest $750 million in U.S. manufacturing expansion
Roche’s biotech unit plans new Hillsboro, Oregon facility as part of a $750 million investment to expand U.S. production capacity.
Siegfried maintains 2026 outlook after 2H gains from U.S., Australia sites
Swiss pharma services group posts 2.2% H1 sales growth to 633M CHF; core EBITDA margin rises to 22.4%. Three newly acquired sites expected to add $100M in 2026 revenue.
Sonic Healthcare posts 13% revenue rise but shares drop on FY2026 outlook
Australia’s largest pathology provider reported A$10.9 billion in revenue for FY2026, up 13% year-over-year, but its stock fell 9.2% after missing earnings expectations and flagging margin pressures in key markets.
Novartis to present cardiovascular data at ESC Congress 2026
Ten abstracts across Novartis's cardiovascular portfolio will highlight Leqvio, abelacimab and Entresto, including late-breaking Phase IV trial results and Lp(a) testing strategies.
Telix Pharmaceuticals posts 146% EBITDA surge in H1 2026 as revenue climbs 22%
Precision medicine sales rose 27% year-over-year to $388 million, while full-year revenue guidance maintained at $950M-$970M. EBITDA reached $52M, up from $21M in H1 2025.
Tempus AI jumps 13% on strong earnings, AI platform validation
Chicago-based AI precision medicine firm reports first quarterly profit, raises 2026 revenue guidance after PRISM2 validation study and commercial partnership. Stock hits session high of $59.04.
Straumann shares slide after surprise CEO departure announcement
Dental implant maker’s stock fell as much as 9.5% at open after Guillaume Daniellot’s abrupt exit, later paring losses to 6.2%. Analysts cite uncertainty despite solid half-year results.
Straumann reports 2.3% revenue growth in H1, CEO Daniellot to step down
Swiss dental implant maker posts 1.38 billion francs in first-half sales, trims full-year outlook amid leadership transition.
Straumann posts 7.8% organic revenue growth in H1, confirms 2026 outlook
Zahnimplantatehersteller Straumann reports 2.3% total revenue growth to CHF 1.38 billion in H1, with organic sales up 7.8%. CEO transition announced as Daniellot steps down after seven years.